-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LRUI6G+ooQhwehjdnS6B3jjA+5DSSj8HDwExau+pRr4ufA6Y5XEAvrTGmzUsLz8n 15dUoR2AB9gFwqCcGSPC4g== 0000936392-03-000546.txt : 20030425 0000936392-03-000546.hdr.sgml : 20030425 20030425152235 ACCESSION NUMBER: 0000936392-03-000546 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030425 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20030425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ILLUMINA INC CENTRAL INDEX KEY: 0001110803 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 330804655 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30361 FILM NUMBER: 03664621 BUSINESS ADDRESS: STREET 1: 9885 TOWNE CENTRE DRIVE STREET 2: . CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582024500 MAIL ADDRESS: STREET 1: 9885 TOWN CENTRE DRIVE STREET 2: . CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 a89518e8vk.htm FORM 8-K Illumina, Inc.
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2003

Illumina, Inc.
(Exact name of registrant as specified in its charter)

000-30361
(Commission File Number)

     
Delaware
(State or other jurisdiction of
incorporation)		   33-0804655
(I.R.S. Employer Identification No.)

9885 Towne Centre Drive, San Diego, CA 92121
(Address of principal executive offices, with zip code)

(858) 202-4500
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

 

Item 7. Financial Statements and Exhibits.
Item 9. Regulation FD Disclosure.
SIGNATURES
EXHIBIT 99.1

Table of Contents

Item 7. Financial Statements and Exhibits.

  (c)   Exhibits.

     
99.1   Press release dated April 23, 2003 announcing Illumina Inc.’s financial results for the quarter ended March 30, 2003.

Item 9. Regulation FD Disclosure.

       On April 23, 2003, Illumina, Inc. issued a press release announcing financial results for the quarter ended March 30, 2003. A copy of this press release is attached hereto as Exhibit 99.1. The information contained in this Item 9 is furnished pursuant to Item 12 of Form 8-K “Results of Operations and Financial Condition,” in accordance with SEC Release No. 33-8216. This information and the exhibits hereto, are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of, or otherwise regarded as filed under, the Securities and Exchange Act of 1934, as amended. The information in this report shall not be incorporated by reference into any filing of Illumina, Inc. with the SEC, whether made before or after the date hereof, regardless of any general incorporation language in such filings.

-2-

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    ILLUMINA, INC.
         
         
Date: April 25, 2003   By:   /s/ TIMOTHY M. KISH
Timothy M. Kish
Chief Financial Officer

-3- EX-99.1 3 a89518exv99w1.txt EXHIBIT 99.1 EXHIBIT 99.1 [ILLUMINA LOGO] Illumina, Inc NR200308 Contacts: Jay Flatley Timothy Kish President & CEO Chief Financial Officer 1.858.202.4501 1.858.202.4508 jflatley@illumina.com tkish@illumina.com ILLUMINA REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2003 SAN DIEGO, CALIFORNIA, April 23, 2003 -- Illumina, Inc. (NASDAQ: ILMN) announced today its financial results for the first quarter and three-month period ended March 30, 2003. For the quarter ended March 30, 2003, the Company reported a net loss of $9.0 million, or $0.28 per share, compared to a net loss of $8.7 million, or $0.28 per share, in the first quarter of 2002. Revenues for the first quarter were $4.3 million, compared to $1.3 million for the same period in 2002. Cash and investments at March 30, 2003 totaled $60.4 million. Commenting on the period's results, Jay Flatley, President and CEO, said, "We're pleased to report that compared to the same quarter in 2002, we increased revenue by over 225% and recorded revenue from the first sale of our production-scale genotyping system. We completed installation of a one million genotype-per-day production system at The Wellcome Trust Sanger Institute, laying the foundation for follow-on sales of oligos, reagents, and Sentrix(TM) array matrices." During the quarter, Illumina announced an additional agreement with Genome Quebec to purchase its one million genotype-per-day production system. Genome Quebec and The Sanger Institute respectively represent Canada and the United Kingdom in the International HapMap Project. As a result of these two sales, BeadArray(TM) technology will now be used to map at least 50% of the haplotypes in this $100 million global initiative. Commenting further on the quarter, Flatley noted, "We completed development of and launched our first standard Oligator(TM) product, a high-performance human genome oligo set designed for researchers spotting their own microarrays for gene expression profiling. We worked closely with leading academic researchers on product design and testing, and are offering this oligo set at a significant price advantage to existing products on the market." OTHER QUARTERLY NEWS AND HIGHLIGHTS - - Illumina introduced an extensive set of over 40,000 SNP assays for genome-wide scans and for fine mapping of chromosomal regions. The SNPs are distributed evenly across the genome and are packaged to allow researchers wide flexibility in experimental design. - - Our new Japanese subsidiary, Illumina K.K., began commercial operation, continuing the planned build-out of international sales and distribution capability. Illumina K.K. is staffed by four employees with extensive experience serving the Japanese life science market, including pharmaceutical firms, leading universities, and genome centers. - - Illumina developed and introduced a second-generation genetic linkage mapping panel with 3500 loci distributed across the genome. This standard genotyping product further reduces the cost and time to complete familial linkage studies compared to other technologies on the market. A significant portion of Illumina's current revenue is derived from large, individual transactions such as the sale of production genotyping systems or genotyping services contracts. In addition, uncertain spending patterns in our markets could affect demand for some of Illumina's products over the coming quarters. Given the difficulty in predicting the timing and magnitude of sales for Illumina's product offerings, the Company may experience some quarter-to-quarter fluctuations in revenue during the year, including the potential for an occasional sequential revenue decline. Illumina (www.illumina.com) is developing next-generation tools for the large-scale analysis of genetic variation and function. The information provided by these analyses will enable the development of personalized medicine, a key goal of genomics and proteomics. The Company's proprietary BeadArray technology provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will correlate genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in any forward-looking statements are Illumina's ability to fully develop and commercialize its BeadArray technologies, the costs and outcome of Illumina's litigation with Applied Biosystems, the Company's ability to successfully commercialize its integrated systems for high-throughput SNP genotyping, to continue to attract and retain customers in its services and oligonucleotide synthesis operations, to fully develop its BeadArray technologies, to develop and deploy new gene expression profiling and proteomics applications for its platform technology, to manufacture robust Sentrix arrays for product sale, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. ILLUMINA, INC. CONDENSED STATEMENTS OF OPERATIONS (IN THOUSANDS EXCEPT PER SHARE AMOUNTS)
THREE MONTHS ENDED -------------------------- MARCH 30, MARCH 31, 2003 2002 -------------------------- (UNAUDITED) Revenue: Product $ 1,407 $ 540 Service 1,867 -- Research 1,002 729 ---------------------- Total revenue 4,276 1,269 Costs and expenses: Cost of revenue 1,910 339 Research and development 5,722 7,092 Selling, general and administrative 4,580 1,642 Amortization of deferred compensation and other non-cash compensation charges 865 1,225 Litigation judgment 189 -- ---------------------- Total costs and expenses 13,266 10,298 ---------------------- Loss from operations (8,990) (9,029) Interest income, net 30 362 ---------------------- Net loss $ (8,960) $ (8,667) ====================== Net loss per share, basic and diluted $ (0.28) $ (0.28) ====================== Shares used in calculating net loss per share, basic and diluted 31,584 30,455 ======================
ILLUMINA, INC. CONDENSED BALANCE SHEETS (IN THOUSANDS)
MARCH 30, DECEMBER 29, 2003 2002 ------------- ------------- (UNAUDITED) (NOTE) ASSETS Current assets: Cash and investments $ 60,385 $ 66,294 Other current assets 5,785 6,525 -------- -------- Total current assets 66,170 72,819 Property and equipment, net 48,076 48,279 Intangible and other assets, net 973 808 -------- -------- Total assets $115,219 $121,906 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities $ 15,656 $ 14,297 Long-term debt and liabilities 35,677 35,865 Stockholders' equity 63,886 71,744 -------- -------- Total liabilities and stockholders' equity $115,219 $121,906 ======== ========
Note: The Balance Sheet at December 29, 2002 has been derived from the audited financial statements as of that date. # # # -----END PRIVACY-ENHANCED MESSAGE-----